Trade Names:Aventyl Hydrochloride Pulvules- Capsules 10 mg- Capsules 25 mg
Trade Names:Pamelor- Capsules 10 mg- Capsules 25 mg- Capsules 50 mg- Capsules 75 mg- Solution 10 mg base/5 mLApo-Nortriptyline (Canada)Gen-Nortriptyline (Canada)ratio-Nortriptyline (Canada)
Inhibits reuptake of norepinephrine and serotonin in CNS.
Relief of symptoms of depression.
Treatment of panic disorder, premenstrual depression, dermatologic disorders (eg, chronic urticaria, angioedema, nocturnal pruritus in atopic eczema).
Hypersensitivity to any tricyclic antidepressant. Generally, not to be given in combination with or within 14 days of treatment with MAOIs or during acute recovery phases of MI.
PO 25 mg 3 times daily to 4 times daily. Doses more than 150 mg/day are not recommended.Elderly and Adolescents
PO 30 to 50 mg/day in divided doses.
Store at room temperature (59° to 86°F) in tight container.
Dicumaral actions may increase.Carbamazepine
Carbamazepine levels may increase; nortriptyline levels may decrease.Cimetidine, fluoxetine
Coadministration may increase nortriptyline blood levels and effects.CNS depressants
Depressant effects may be additive.Clonidine
May result in hypertensive crisis.Guanethidine
Hypotensive action may be inhibited.MAO Inhibitors
Hyperpyretic crisis, convulsions and death may occur.Sympathomimetics
Pressor response may decrease.
None well documented.
Orthostatic hypotension; hypertension; tachycardia; palpitations; arrhythmias; ECG changes; stroke; heart block; CHF.
Confusion; hallucinations; delusions; nervousness; restlessness; agitation; panic; insomnia; nightmares; mania; exacerbation of psychosis; drowsiness; dizziness; weakness; fatigue; emotional lability; seizures; tremors; extrapyramidal symptoms (eg, pseudoparkinsonism, movement disorders, akathisia).
Rash; pruritus; photosensitivity reaction; dry skin; acne.
Nasal congestion; tinnitus; conjunctivitis; mydriasis; blurred vision; increased IOP; peculiar taste in mouth.
Nausea; vomiting; anorexia; GI distress; diarrhea; flatulence; dry mouth; constipation.
Impotence; sexual dysfunction; nocturia; urinary frequency; urinary tract infection; vaginitis; cystitis; dysmenorrhea; amenorrhea; urinary retention and hesitancy.
Bone marrow depression including agranulocytosis; eosinophilia; purpura; thrombocytopenia; leukopenia.
Elevation or depression of blood sugar.
Pharyngitis; rhinitis; sinusitis; laryngitis; coughing.
Numbness; breast enlargement.
Category D . Safety not established. Limb reduction anomalies have been reported with nortriptyline.
Excreted in breast milk.
Safety and efficacy not established.
Use drug with caution in patients with history of seizures, urinary retention, urethral or ureteral spasm, angle-closure glaucoma or increased IOP, CV disorders, hyperthyroid patients or those receiving thyroid medication, patients with hepatic or renal impairment, schizophrenia, or paranoia.
Confusion, vomiting, muscle rigidity, ECG abnormalities, seizures, agitation, fever, hyperactive reflexes, CHF, coma, respiratory depression, death.
Copyright © 2009 Wolters Kluwer Health.